<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002145'>Frontotemporal dementia</z:hpo> regards a group of presenile progressive neurodegenerative form of <z:hpo ids='HP_0000726'>dementias</z:hpo> which includes <z:e sem="disease" ids="C0236642" disease_type="Disease or Syndrome" abbrv="">Pick's disease</z:e>, <z:e sem="disease" ids="C0393570" disease_type="Disease or Syndrome" abbrv="">corticobasal degeneration</z:e>, <z:hpo ids='HP_0002145'>frontotemporal dementia</z:hpo> with <z:e sem="disease" ids="C0085084" disease_type="Disease or Syndrome" abbrv="">motor neuron disease</z:e>, <z:e sem="disease" ids="C0338454" disease_type="Disease or Syndrome" abbrv="">frontal lobe degeneration</z:e>, <z:hpo ids='HP_0000726'>dementia</z:hpo>-<z:hpo ids='HP_0001300'>parkinsonism</z:hpo>-<z:hpo ids='HP_0003202'>amyotrophy</z:hpo> complex, familial non-specific <z:hpo ids='HP_0000726'>dementia</z:hpo> mapping to chromosome 3, non-Alzheimer degenerative <z:hpo ids='HP_0000726'>dementia</z:hpo> lacking distinctive histological features as well as a number other infrequent syndromes with <z:hpo ids='HP_0000726'>dementia</z:hpo> and focal neurological signs </plain></SENT>
<SENT sid="1" pm="."><plain>The aim of this study was to investigate the regional distribution of metallothionein-I-II, an ubiquitary group of buffering proteins, in cases of <z:hpo ids='HP_0002145'>frontotemporal dementia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>The aim of the present study was to study the metallothionein-I-II expression in relationship to the expression in astrocytes of glial fibrillary acidic protein (GFAP) as we have already done in previous studies of Alzheimer's and <z:e sem="disease" ids="C0270786" disease_type="Disease or Syndrome" abbrv="">Binswanger's diseases</z:e> [31,32] </plain></SENT>
<SENT sid="3" pm="."><plain>Our findings indicate that metallothionein-I-II expression in the most affected areas is likely to be regionally distinct and layer-dependent, in that it is highest in the deep layers of the frontotemporal cortex and the allocortex (hippocampus) while insignificantly immunopositive in the occipital cortex </plain></SENT>
<SENT sid="4" pm="."><plain>In addition, the potential use of metallothionein-I-II as a new pharmacological approach to contrast some deleterious aspects of this disease has been also discussed </plain></SENT>
</text></document>